Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes

Postgraduate Medicine

Volumn 122, Issue 2, 2010, Pages 112-120

  Florez, Hermes ^a   Luo, Jiacong ^a   Castillo Florez, Sumaya ^a   Mitsi, Georgia ^a   Hanna, John ^a   Tamariz, Leonardo ^a   Palacio, Ana ^a   Nagendran, Sukumar ^b   Hagan, Michael ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

Adherence; Health related quality of life; Metformin; Type 2 diabetes

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOATING; BOWEL SYMPTOM QUESTIONNAIRE; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; FEMALE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRESCRIPTION; QUALITY OF LIFE; QUESTIONNAIRE; RETCHING; SHORT FORM 36; TELEPHONE; CHEMICALLY INDUCED DISORDER; CONFIDENCE INTERVAL; GASTROINTESTINAL DISEASE; HEALTH SURVEY; INFORMATION PROCESSING; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; RISK; RISK FACTOR; STATISTICAL MODEL; STATISTICS; UNITED STATES;

AGED; CONFIDENCE INTERVALS; DATA COLLECTION; DIABETES MELLITUS, TYPE 2; FEMALE; GASTROINTESTINAL DISEASES; HEALTH STATUS INDICATORS; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; METFORMIN; ODDS RATIO; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; UNITED STATES;

EID: 77950346254     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.03.2128     Document Type: Article

References (23)

1. Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care. 2002;25(12):2238-2243.
2. Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life: a population study. Diabetes Care. 2004;27(5):1066-1070.
3. Manuel DG, Schultz SE. Health-related quality of life and healthadjusted life expectancy of people with diabetes in Ontario, Canada,1996-1997. Diabetes Care. 2004;27(2):407-414.
4. Lloyd A, Sawyer W, Hopkinson P. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin. Value Health. 2001;4(5):392-400.
5. Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002;25(3):458-463.
6. U.K. Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care. 1999;22(7):1125-1136.
7. Quan C, Talley NJ, Jones MP, Spies J, Horowitz M. Gain and loss of gastrointestinal symptoms in diabetes mellitus: associations with psychiatric disease, glycemic control, and autonomic neuropathy over 2 years of follow-up. Am J Gastroenterol. 2008;103(8):2023-2030.
8. Siddique R, Ricci JA, Stewart WF, Sloan S, Farup CE. Quality of life in a US national sample of adults with diabetes and motility-related upper gastrointestinal symptoms. Dig Dis Sci. 2002;47(4):683-689.
9. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161(16):1989-1996.
10. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963-1972.
11. Hoffmann IS, Roa M, Torrico F, Cubeddu LX. Ondansetron and metformin-induced gastrointestinal side effects. Am J Ther. 2003;10(6):447-451.
12. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20(4):565-572.
13. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137(1):25-33.
14. Talley NJ, Young L, Bytzer P, et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am J Gastroenterol. 2001;96(1):71-76.
15. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483.
16. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407-415.
17. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003;1:4.
18. Kontodimopoulos N, Pappa E, Papadopoulos AA, Tountas R, Niakas D. Comparing SF-6D and EQ-5D utilities across groups differing in health status. Qual Life Res. 2009;18(1):87-97.
19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
20. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphospphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089-1096.
21. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33(6):1014-1029; discussion1030-1011.
22. Kalsekar ID, Madhavan SS, Amonkar MM, et al. Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycemic agents. Ann Pharmacother. 2006;40(4):605-611.
23. Walker EA, Molitch M, Kramer MK, et al. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care. 2006;29(9):1997-2002.